|
Briefing
|
- QB – Virus-like particle manufactured by MSU scientists that can generate anti-cancer immune responses in body, which could potentially lead to development of cancer treatment for humans
- How It Works – Links QB particles with Tumor-associated carbohydrate antigens (TACA) (i.e. unique structures present on many cancer cells, but not healthy cells), to effectively teach immune cells to destroy anything with TACA
- Grant Funding – National Cancer Institute awarded MSU researchers with $2.4 million to develop new anti-cancer immunotherapy, complementing current treatment regimens, such as chemotherapy and radiotherapy
- Animal Treatment – Vaccine will first be administered on canine cancer patients, focusing on osteosarcoma (i.e. bone tumor in dogs and humans)
|
|
Accelerator
|
|
|
Sector
|
Healthcare/Health Sciences
|
|
Organization
|
Michigan State University
|
|
Source
|
-
Brooks, C. and Lenhard, E., "Virus-like particle could lead to new cancer vaccine",
-
Galeon, D. and Reedy, C., "Researchers are developing a new cancer vaccine using virus-like particles",
-
Lenhard, E., "MSU natural science, veterinary medicine partner in cancer vaccine research",
-
AcceleratingBiz analysis
|
|
Original Publication Date
|
March 1, 2018
|
